X4 Pharmaceuticals, Inc insider trading
Every open-market purchase and sale by X4 Pharmaceuticals, Inc's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
Insider purchases, 5 years $261,881 2 trades by 1 insider
3 months later: median +21.7% (+18.8% vs S&P 500) Insider sales, 5 years $462,547 5 trades by 3 insiders
3 months later: median −19.6% (−23.2% vs S&P 500)
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following X4 Pharmaceuticals, Inc’s insiders pay?
From August 11, 2023 to October 19, 2026, 10 insiders reported 4 open-market purchases and 10 sales not made under a pre-set plan in X4 Pharmaceuticals, Inc.
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Craig Adam R | Executive Chairman | 2 | — | — | 1 | — | October 19, 2026 |
| Kirske David | Chief Financial Officer | 0 | — | — | 3 | — | October 5, 2026 |
| Baldry Mark | Chief Commercial Officer | 1 | — | — | 0 | — | February 14, 2025 |
| Dibiase Mary | Chief Operating Officer | 0 | — | — | 1 | — | March 11, 2024 |
| Mostafa Adam S. | Chief Financial Officer | 0 | — | — | 1 | — | March 11, 2024 |
| Ragan Paula | President and CEO | 0 | — | — | 1 | — | March 11, 2024 |
| Stewart Murray | Interim Chief Medical Officer | 0 | — | — | 1 | — | August 11, 2023 |
| Taveras Arthur | Chief Scientific Officer | 0 | — | — | 1 | — | March 11, 2024 |
| Volpone John | President | 0 | — | — | 1 | — | August 13, 2026 |
| Wyzga Michael S | Director | 1 | — | — | 0 | — | August 22, 2023 |